Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving considerations for treatment navigation in EGFR-mutant NSCLC.
Addressing the Most Critical Questions in EGFR-Mutant Advanced NSCLC
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer
2
FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan for Neuroendocrine Carcinomas
3
NCCN Guidelines Add Gedatolisib-Based Regimens for Pretreated PIK3CA Wild-Type Advanced Breast Cancer
4
Frontline Zanubrutinib Plus Obinutuzumab Elicits Complete Responses in Older Patients With MCL
5